Integrating SENOMAC and AMAROS: a call for de-escalation.
作者信息
Diaz Raquel, Allievi Rebecca, Fregatti Piero
机构信息
Department of Surgical and Diagnostic Integrated Sciences-DISC, University of Genova, 16132, Genoa, Italy.
Breast Surgery, IRCCS Ospedale Policlinico San Martino, 16132, Genoa, Italy.
出版信息
Breast Cancer Res Treat. 2025 Jul;212(2):415-416. doi: 10.1007/s10549-025-07743-1. Epub 2025 May 26.
Abstract
摘要
相似文献
1
Integrating SENOMAC and AMAROS: a call for de-escalation.整合SENOMAC和AMAROS：呼吁降级治疗。
Breast Cancer Res Treat. 2025 Jul;212(2):415-416. doi: 10.1007/s10549-025-07743-1. Epub 2025 May 26.
2
Clinical Experience of Axillary Radiotherapy for Node-positive Breast Cancer.腋窝放疗治疗淋巴结阳性乳腺癌的临床经验。
Clin Oncol (R Coll Radiol). 2024 Feb;36(2):98-106. doi: 10.1016/j.clon.2023.11.040. Epub 2023 Nov 28.
3
The generalisability of randomised clinical trials: an interim external validity analysis of the ongoing SENOMAC trial in sentinel lymph node-positive breast cancer.随机临床试验的推广性：正在进行的前哨淋巴结阳性乳腺癌 SENOMAC 试验的中期外部有效性分析。
Breast Cancer Res Treat. 2020 Feb;180(1):167-176. doi: 10.1007/s10549-020-05537-1. Epub 2020 Jan 27.
4
Completion axillary lymph node dissection for the identification of pN2-3 status as an indication for adjuvant CDK4/6 inhibitor treatment: a post-hoc analysis of the randomised, phase 3 SENOMAC trial.完成腋窝淋巴结清扫术以确定 pN2-3 状态作为辅助 CDK4/6 抑制剂治疗的指征：随机、III 期 SENOMAC 试验的事后分析。
Lancet Oncol. 2024 Sep;25(9):1222-1230. doi: 10.1016/S1470-2045(24)00350-4. Epub 2024 Aug 6.
5
Axillary clearance and chemotherapy rates in ER+HER2- breast cancer: secondary analysis of the SENOMAC trial.雌激素受体阳性、人表皮生长因子受体2阴性乳腺癌的腋窝清扫率和化疗率：SENOMAC试验的二次分析
Lancet Reg Health Eur. 2024 Sep 26;47:101083. doi: 10.1016/j.lanepe.2024.101083. eCollection 2024 Dec.
6
When Less Can Be More: How the 10-Year Updated Results From the Randomized Controlled AMAROS Trial Should Affect Axillary Management in the Setting of a Positive Node.从随机对照 AMAROS 试验的 10 年更新结果看，当更少可以成为更多：其对阳性淋巴结时腋窝管理的影响。
J Clin Oncol. 2023 Apr 20;41(12):2144-2150. doi: 10.1200/JCO.22.02070. Epub 2023 Feb 27.
7
Should abemaciclib candidacy be an indication for ALND?-commentary on SENOMAC post-hoc analysis.阿贝西利的适用情况是否应作为腋窝淋巴结清扫术的指征？——关于SENOMAC事后分析的评论
Gland Surg. 2025 Apr 30;14(4):776-780. doi: 10.21037/gs-2025-38. Epub 2025 Apr 25.
8
Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19.儿科疫苗试验中年龄降级的伦理问题：关注 COVID-19 案例。
Vaccine. 2023 Feb 24;41(9):1584-1588. doi: 10.1016/j.vaccine.2023.01.055. Epub 2023 Jan 27.
9
Development and evaluation of a de-escalation training intervention in adult acute and forensic units: the EDITION systematic review and feasibility trial.成人急症和法医病房中降级治疗培训干预措施的制定和评估：EDITION 系统评价和可行性试验。
Health Technol Assess. 2024 Jan;28(3):1-120. doi: 10.3310/FGGW6874.
10
Is mental health staff training in de-escalation techniques effective in reducing violent incidents in forensic psychiatric settings? - A systematic review of the literature.在法医精神病学环境中，进行心理卫生人员的降级技术培训是否能有效减少暴力事件？——文献系统评价。
BMC Psychiatry. 2023 Apr 12;23(1):246. doi: 10.1186/s12888-023-04714-y.
本文引用的文献
1
Omitting Axillary Dissection in Breast Cancer with Sentinel-Node Metastases.省略腋窝清扫术治疗前哨淋巴结转移乳腺癌。
N Engl J Med. 2024 Apr 4;390(13):1163-1175. doi: 10.1056/NEJMoa2313487.
2
Radiotherapy or Surgery of the Axilla After a Positive Sentinel Node in Breast Cancer: 10-Year Results of the Randomized Controlled EORTC 10981-22023 AMAROS Trial.乳腺癌前哨淋巴结阳性后腋窝放疗或手术：EORTC 10981-22023 AMAROS 试验的 10 年随机对照结果。
J Clin Oncol. 2023 Apr 20;41(12):2159-2165. doi: 10.1200/JCO.22.01565. Epub 2022 Nov 16.
3
Contemporary Axillary Management in cT1-2N0 Breast Cancer with One or Two Positive Sentinel Lymph Nodes: Factors Associated with Completion Axillary Lymph Node Dissection Within the National Cancer Database.在 cT1-2N0 乳腺癌中，有 1 或 2 个阳性前哨淋巴结的当代腋窝管理：国家癌症数据库中与完成腋窝淋巴结清扫术相关的因素。
Ann Surg Oncol. 2022 Aug;29(8):4740-4749. doi: 10.1245/s10434-022-11759-y. Epub 2022 Apr 22.
Zotero 插件